Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus chemotherapy in resistant advanced gastric cancer
NCT05751265Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jul 2023
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of tislelizumab in gastric cancer (GC), sponsored by Fujian Medical University Cancer Hospital. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05751265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751265.